oral glp 1 inhibitor The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

Mutagenesis 2006

Additionally, lixisenatide was tested in a large cardiovascular safety trial ( ELIXA , in post-heart-attack diabetic patients) and was found cardiovascularly neutral it neither increased nor decreased CV events versus placebo ( [128] )

Further research may enhance our understanding of the mechanisms by which the combination of GLP-1RAs and SGLT2is acts to derive a cardiovascular benefit

The Bottom Line The Alzheimer's Association has launched the largest dementia prevention trial in history $100 million, global enrollment, testing whether GLP-1 drugs combined with a proven lifestyle intervention can prevent cognitive decline before it begins